Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient demographics and clinicopathological characteristics for Stage I, II, III patients with HER2-positive breast cancer

From: Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

At time of diagnosis of index cancer     
Variable
N (%)
Total
(N = 3394)
HR-positive
(n = 2015)
HR-negative
(n = 1379)
P-value
Age, mean (se), y 52.48 (0.21) 52.41 (0.29) 52.59 (0.32)  
Age category, N, (%)     <.001
0 to <50 1,514 (45) 931 (46) 583 (42)  
50 to <70 1,547 (46) 865 (43) 682 (49)  
70+ 333 (10) 219 (11) 114 (8)  
Race/Ethnicity, N, (%)     0.030
African-American 259 (8) 135 (7) 124 (9)  
Caucasian 2,693 (79) 1,627 (81) 1,066 (77)  
Hispanic 262 (8) 155 (8) 107 (8)  
Asian Pacific Island 126 (4) 64 (3) 62 (5)  
American Indian 10 (<1) 4 (<1) 6 (<1)  
Other 16 (<1) 10 (1) 6 (<1)  
Unknown 28 (1) 20 (1) 8 (1)  
Menopausal Status, N, (%)     0.001
Premenopausal 1,569 (46) 978 (49) 591 (43)  
Postmenopausal 1,825 (54) 1,037 (51) 788 (57)  
Body Mass Index kg/m2, N, (%)     0.512
<18.5 kg/m2 (Underweight) 52 (2) 34 (2) 18 (1)  
18.5 to <25 kg/m2 (Normal) 1,263 (37) 750 (37) 513 (37)  
25 to <30 kg/m2 (Obese) 913 (27) 554 (27) 359 (26)  
>30 kg/m2 (Severely Obese) 884 (26) 506 (25) 378 (27)  
Missing/unknown 282 (8) 171 (8) 111 (8)  
Co-morbidity score, N, (%)     0.958
0 2,713 (80) 1,609 (80) 1,104 (80)  
1 452 (13) 271 (13) 181 (13)  
2+ 229 (7) 135 (7) 94 (7)  
Method of detection, N, (%)     <.001
Abnormal screening mammogram 1,209 (36) 755 (37) 454 (33)  
Symptom 2,012 (59) 1,175 (58) 837 (61)  
Other 147 (4) 67 (3) 80 (6)  
Unknown 26 (1) 18 (1) 8 (1)  
T stage, category, N, (%)     <.001
T1 1,753 (52) 1,103 (55) 650 (47)  
T2 1,150 (34) 691 (34) 459 (33)  
T3 244 (7) 129 (6) 115 (8)  
T4 197 (6) 73 (4) 124 (9)  
Unknown 50 (1) 19 (1) 31 (2)  
Nodal status, N, (%)     <.001
Positive 1,623 (48) 907 (45) 716 (52)  
Negative 1,757 (52) 1,101 (55) 656 (48)  
Unknown 14 (<1) 7 (<1) 7 (<1)  
AJCC stage, N, (%)     <.001
I 1,187 (35) 772 (38) 415 (30)  
II 1,467 (43) 887 (44) 580 (42)  
III 740 (22) 356 (18) 384 (28)  
Histologic grade, N, (%)     <.001
Low/Intermediate 907 (27) 719 (36) 188 (14)  
High 2,324 (68) 1,211 (60) 1,113 (81)  
Unknown 163 (5) 85 (4) 78 (6)  
Histology, N, (%)     <.001
Invasive ductal 3,101 (91) 1,772 (88) 1,329 (97)  
Invasive lobular 105 (3) 89 (4) 16 (1)  
Mixed ductal and lobular 139 (4) 120 (6) 19 (1)  
Other 49 (1) 34 (2) 15 (1)  
LVI, N, (%)     0.630
Presence 1,164 (34) 678 (34) 486 (35)  
Absence 2,113 (62) 1,267 (63) 846 (61)  
Unknown 117 (3) 70 (3) 47 (3)  
EIC, N, (%)     0.536
Presence 606 (18) 353 (18) 253 (18)  
Absence 2,788 (82) 1,662 (82) 1,126 (82)  
In patients with documented recurrence     
Variable Total
N = 458
HR-positive
N = 208
HR-negative
N = 250
P -value
Disease free interval median (range), y 1.95 (7.69) 2.24 (7.69) 1.70 (7.08)  
Age, mean (se), y 50.95 (0.60) 50.39 (0.94) 51.41 (0.78)  
Race/Ethnicity, N, (%)     0.644
African-American 51 (11) 21 (10) 30 (12)  
Caucasian 358 (78) 166 (80) 192 (77)  
Hispanic 31 (7) 12 (6) 19 (8)  
Asian Pacific Island 12 (3) 6 (3) 6 (2)  
American Indian 1 (<1) 1 (<1) 0 (0)  
Other 4 (1) 1 (<1) 3 (1)  
Unknown 1 (<1) 1 (<1) 0 (0)  
Menopausal status at time of diagnosis of index cancer, N, (%)     0.207
Premenopausal 223 (49) 108 (52) 115 (46)  
Postmenopausal 235 (51) 100 (48) 135 (54)  
Co-morbidity score at time of diagnosis of index cancer, N, (%)     0.437
0 371 (81) 166 (80) 205 (82)  
1 57 (12) 25 (12) 32 (13)  
2+ 30 (7) 17 (8) 13 (5)  
AJCC stage at time of diagnosis of index cancer, N, (%)     0.437
I 77 (17) 36 (17) 41 (16)  
II 188 (41) 91 (44) 97 (39)  
III 193 (42) 81 (39) 112 (45)  
Histologic grade at time of diagnosis of index cancer, N, (%)     0.016
Low/Intermediate 65 (14) 40 (19) 25 (10)  
High 379 (83) 163 (79) 216 (86)  
Unknown 14 (3) 5 (2) 9 (4)  
  1. Note: AJCC, American Joint Committee on Cancer Staging; EIC, extensive intraductal component; HR, Hormone receptor; LVI, Lymphovascular invasion; se, standard error; y, year